腹腔镜初次肿瘤细胞减灭术在多脏器切除晚期卵巢癌中的前瞻性验证
该前瞻性研究纳入66例III-IV期卵巢癌患者,21例经严格筛选接受腹腔镜初次肿瘤细胞减灭术(LPC),45例接受开腹手术(APC)。LPC组与APC组满意减瘤率(RT=0)分别为95%和88.4%,LPC组无术中并发症、早期术后并发症4例(19%),化疗启动中位时间更短。
要点
- 严格筛选后LPC组满意减瘤率95%,APC组88.4%
- LPC组无术中并发症,早期术后并发症19%
- LPC组化疗启动中位15天,短于APC组28天
核心结论
- 经严格筛选的晚期卵巢癌患者可接受LPC,满意减瘤率极高、围术期并发症可接受、化疗间隔短且生存结局令人鼓舞。
研究设计与样本
- 前瞻性研究,2007年6月至2015年7月纳入66例III-IV期卵巢癌且临床条件允许积极手术的患者。
- 21例经严格筛选标准评估后接受LPC,其余45例接受APC;LPC结束时行超低位耻骨小切口取出标本并手辅助腹腔镜探查确认病灶完全切除。
主要发现
- LPC组满意减瘤(RT=0)率95%,APC组88.4%。
- LPC组无术中并发症,早期术后并发症4例(19%);APC组术中并发症17.8%、早期术后并发症46.7%。
- 化疗启动中位时间LPC组15天(范围10-30),APC组28天(范围20-35)。
- 中位随访51个月,2年无病生存率LPC组76.2%,APC组73.4%。
临床怎么用
- 对晚期卵巢癌患者可依据严格筛选标准评估LPC可行性,筛选合格者行腹腔镜初次肿瘤细胞减灭术。
- LPC结束时应行超低位耻骨小切口取标本并手辅助腹腔镜探查,确认病灶完全切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary cytoreduction is the mainstay of treatment for advanced ovarian cancer (AOC). We developed and prospectively evaluated an algorithm to investigate the possible role of laparoscopic primary cytoreduction (LPC) in carefully selected patients, with AOC. METHODS: From June 2007 to July 2015, all patients with stage III-IV ovarian cancer and clinical conditions allowing aggressive surgery were candidate to primary cytoreduction with the aim of achieving residual tumor (RT) = 0. The possibility of attempting laparoscopic cytoreduction was carefully evaluated using strict selection criteria. The other patients were approached by abdominal primary cytoreduction (APC). At the end of LPC, an ultra-low pubic mini-laparotomy was performed to extract surgical specimens and to accomplish a laparoscopic hand-assisted exploration of the abdominal organs, in order to confirm complete excision of the disease. RESULTS: Of the included 66 patients, 21 were considered eligible for LPC; the remaining 45 underwent APC. Optimal cytoreduction (i.e., RT = 0) was obtained in 95 and 88.4% in the LPC and APC groups, respectively. No intra-operative complication and 4 (19%) early post-operative complications were observed among patients who received LPC. Patients who underwent APC had 17.8 and 46.7% intra- and early post-operative complications, respectively. Median time to initiation of chemotherapy was 15 (range, 10-30) days in the LPC group and 28 (20-35) days in the APC group. After a median follow-up of 51 months, 2-year disease-free survival was 76.2% in the LPC group and 73.4% in the APC group. CONCLUSIONS: After strict selection, a group of patients with AOC may undergo LPC with extremely high rates of optimal cytoreduction, satisfactory perioperative morbidity, a short interval to chemotherapy, and encouraging survival outcomes. Clinical trial registration NCT02980185.
引用
- Ceccaroni M, Roviglione G, Bruni F, et al. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"? Surg Endosc. 2017. PMID: 29052073. doi:10.1007/s00464-017-5899-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。